TY - JOUR
T1 - Quantitation of bleeding symptoms in a national registry of patients with inherited platelet disorders
AU - Revel-Vilk, Shoshana
AU - Richter, Chana
AU - Ben-Ami, Tal
AU - Yacobovich, Joanne
AU - Aviner, Shraga
AU - Ben-Barak, Ayelet
AU - Kuperman, Amir Asher
AU - Ben-Barak, Shira
AU - Kaplinsky, Chaim
AU - Miskin, Hagit
AU - Tamary, Hannah
AU - Kenet, Gili
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background Inherited platelet deficiency and/or dysfunction may be more common in the general population than has previously been appreciated. In 2013 the Israeli Inherited Platelet Disorder (IPD) Registry was established. Methods Clinical and laboratory data were collected to pre-specified registration forms. The study protocol was approved by the local hospital ethics committees. Results To date we have included in the registry 89 patients (male 52%) from 79 families. Most patients (74%) have a not-yet specified inherited thrombocytopenia (n = 39) or non-specific platelet function disorder (n = 27). Full clinical data were available for 81 (91%) patients. The median (range) age at presentation and time of follow-up were 1.8 years (1 day–17.8 years) and 4.7 (0–26) years, respectively. The Pediatric Bleeding Questionnaire was available for 78 patients; abnormal bleeding score (≥ 2) was recorded in 47 (52.8%, 95% CI 42%–63.5%) patients and was less frequent in patients followed for isolated thrombocytopenia. Abnormal score was associated with a longer time of follow-up, OR 1.19 (95% CI 1.04–1.36). Conclusion Long term follow-up of patients with IPDs is important as bleeding risks may increase with time. We expect that clinical and laboratory information of patients/families with IPDs gathered in a systemic format will allow for better diagnosis and treatment of these patients.
AB - Background Inherited platelet deficiency and/or dysfunction may be more common in the general population than has previously been appreciated. In 2013 the Israeli Inherited Platelet Disorder (IPD) Registry was established. Methods Clinical and laboratory data were collected to pre-specified registration forms. The study protocol was approved by the local hospital ethics committees. Results To date we have included in the registry 89 patients (male 52%) from 79 families. Most patients (74%) have a not-yet specified inherited thrombocytopenia (n = 39) or non-specific platelet function disorder (n = 27). Full clinical data were available for 81 (91%) patients. The median (range) age at presentation and time of follow-up were 1.8 years (1 day–17.8 years) and 4.7 (0–26) years, respectively. The Pediatric Bleeding Questionnaire was available for 78 patients; abnormal bleeding score (≥ 2) was recorded in 47 (52.8%, 95% CI 42%–63.5%) patients and was less frequent in patients followed for isolated thrombocytopenia. Abnormal score was associated with a longer time of follow-up, OR 1.19 (95% CI 1.04–1.36). Conclusion Long term follow-up of patients with IPDs is important as bleeding risks may increase with time. We expect that clinical and laboratory information of patients/families with IPDs gathered in a systemic format will allow for better diagnosis and treatment of these patients.
KW - Bleeding assessment tool
KW - Bleeding score
KW - Inherited platelet disorders
KW - Inherited thrombocytopenia
KW - Registry
UR - http://www.scopus.com/inward/record.url?scp=85008233954&partnerID=8YFLogxK
U2 - 10.1016/j.bcmd.2016.11.013
DO - 10.1016/j.bcmd.2016.11.013
M3 - Article
C2 - 27998672
AN - SCOPUS:85008233954
SN - 1079-9796
VL - 67
SP - 59
EP - 62
JO - Blood Cells, Molecules, and Diseases
JF - Blood Cells, Molecules, and Diseases
ER -